| Literature DB >> 28286694 |
Kari E Hernandez1, Hans Renata1, Russell D Lewis2, S B Jennifer Kan1, Chen Zhang3, Jared Forte3, David Rozzell3, John A McIntosh1, Frances H Arnold4.
Abstract
Extending the scope of biocatalysis to important non-natural reactions such as olefin cyclopropanation will open new opportunities for replacing multi-step chemical syntheses of pharmaceutical intermediates with efficient, clean, and highly selective enzyme-catalyzed processes. In this work, we engineered the truncated globin of Bacillus subtilis for the synthesis of a cyclopropane precursor to the antithrombotic agent ticagrelor. The engineered enzyme catalyzes the cyclopropanation of 3,4-difluorostyrene with ethyl diazoacetate on a preparative scale to give ethyl-(1R, 2R)-2-(3,4-difluorophenyl)-cyclopropanecarboxylate in 79% yield, with very high diastereoselectivity (>99% dr) and enantioselectivity (98% ee), enabling a single-step biocatalytic route to this pharmaceutical intermediate.Entities:
Keywords: Bacillus subtilis; biocatalysis; cyclopropanation; directed evolution; ticagrelor; truncated globin
Year: 2016 PMID: 28286694 PMCID: PMC5340201 DOI: 10.1021/acscatal.6b02550
Source DB: PubMed Journal: ACS Catal Impact factor: 13.084